Danirixin

DB11922InvestigationalSmall molecule

Danirixin has been used in trials studying the treatment and basic science of Virus Diseases, Nutritional Status, Pulmonary Disease, Chronic Obstructive, and Infections, Respiratory Syncytial Virus.

Mechanism: Pharmacologically active on C-X-C chemokine receptor type 2
Curator reviewed
Formula / weight: C₁₉H₂₁ClFN₃O₄S · 441.9 g/mol (avg)
Code names: GSK1325756 · GSK-1325756B

Resolves to

Compound

UNIIR318PGH5VPCAS954126-98-8ChEMBLCHEMBL3039531PubChem24780598

Structure

InChIKeyNGYNBSHYFOFVLS-LBPRGKRZSA-NSMILESCC1=C(NC(=O)NC2=CC=C(Cl)C(=C2O)S(=O)(=O)[C@H]2CCCNC2)C=CC=C1F

Targets

P25025CXCR2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Danirixin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account